Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1574-1584
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1574
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1574
Figure 1 RASSF1A methylation rate in plasma.
A: RASSF1A methylation rate in plasma of colorectal cancer (CRC), colorectal polyps and T1-T4 stage of CRC; B: RASSF1A methylation rate in plasma of hepatocellular carcinoma (HCC), liver cirrhosis and T1-T4 stage of HCC. CRC: Colorectal cancer; CRP: Colorectal polyps; HCC: Hepatocellular carcinoma; LC: Liver cirrhosis.
Figure 2 Diagnostic value evaluation of RASSF1A methylation rate in plasma for discriminating colorectal cancer, colorectal polyps, hepatocellular carcinoma, and liver cirrhosis.
A: Colorectal cancer and colorectal polyps; B: Hepatocellular carcinoma and liver cirrhosis.
Figure 3 Diagnostic value evaluation of RASSF1A methylation rate in plasma for discriminating T1-T4 stage colorectal cancer and colorectal polyps.
A: T1 stage colorectal cancer (CRC) and colorectal polyps (CRP); B: T2 stage CRC and CRP; C: T3 stage CRC and CRP; D: T4 stage CRC and CRP.
Figure 4 Diagnostic value evaluation of RASSF1A methylation rate in plasma for discriminating T1-T4 stage hepatocellular carcinoma and liver cirrhosis.
A: T1 stage hepatocellular carcinoma (HCC) and liver cirrhosis (LC); B: T2 stage HCC and LC; C: T3 stage HCC and LC; D: T4 stage HCC and LC.
- Citation: Li J, Li H, Run ZC, Wang ZL, Jiang T, An Y, Li Z. RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma. World J Gastrointest Oncol 2022; 14(8): 1574-1584
- URL: https://www.wjgnet.com/1948-5204/full/v14/i8/1574.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i8.1574